Abstract
Early stage (T1-2, N0-1) oral squamous cell carcinoma (OSCC) has a generally favorable prognostic outcome. However, locoregional recurrences can occur in up to 30–35% of patients, and 20% will eventually die of disease. National and international treatment guidelines do not recommend the use of postoperative radiotherapy (PORT) in a setting of early OSCC, and highlight surgery alone as the standard single modality treatment. Notwithstanding, the negative prognostic impact of some adverse pathological features, such as perineural and lymphovascular invasion, poor differentiation, depth of invasion >4 mm, and presence of nodal metastasis, is well known. The advantages of PORT in such scenarios are still debated. The aim of this study was to review the more recent literature to provide evidence on the benefits of PORT in the context of early stage OSCC.
| Original language | English |
|---|---|
| Pages (from-to) | 67-75 |
| Number of pages | 9 |
| Journal | Critical Reviews in Oncology/Hematology |
| Volume | 143 |
| DOIs | |
| Publication status | Published - Nov 2019 |
Fingerprint
Keywords
- Adverse pathological feature
- Early stage oral cavity cancer
- Postoperative radiotherapy
ASJC Scopus subject areas
- Hematology
- Oncology
Cite this
Postoperative radiotherapy (PORT) for early oral cavity cancer (pT1-2,N0-1) : A review. / Ivaldi, Eliana; Di Mario, Dalila; Paderno, Alberto; Piazza, Cesare; Bossi, Paolo; Iacovelli, Nicola Alessandro; Incandela, Fabiola; Locati, Laura; Fallai, Carlo; Orlandi, Ester.
In: Critical Reviews in Oncology/Hematology, Vol. 143, 11.2019, p. 67-75.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Postoperative radiotherapy (PORT) for early oral cavity cancer (pT1-2,N0-1)
T2 - A review
AU - Ivaldi, Eliana
AU - Di Mario, Dalila
AU - Paderno, Alberto
AU - Piazza, Cesare
AU - Bossi, Paolo
AU - Iacovelli, Nicola Alessandro
AU - Incandela, Fabiola
AU - Locati, Laura
AU - Fallai, Carlo
AU - Orlandi, Ester
PY - 2019/11
Y1 - 2019/11
N2 - Early stage (T1-2, N0-1) oral squamous cell carcinoma (OSCC) has a generally favorable prognostic outcome. However, locoregional recurrences can occur in up to 30–35% of patients, and 20% will eventually die of disease. National and international treatment guidelines do not recommend the use of postoperative radiotherapy (PORT) in a setting of early OSCC, and highlight surgery alone as the standard single modality treatment. Notwithstanding, the negative prognostic impact of some adverse pathological features, such as perineural and lymphovascular invasion, poor differentiation, depth of invasion >4 mm, and presence of nodal metastasis, is well known. The advantages of PORT in such scenarios are still debated. The aim of this study was to review the more recent literature to provide evidence on the benefits of PORT in the context of early stage OSCC.
AB - Early stage (T1-2, N0-1) oral squamous cell carcinoma (OSCC) has a generally favorable prognostic outcome. However, locoregional recurrences can occur in up to 30–35% of patients, and 20% will eventually die of disease. National and international treatment guidelines do not recommend the use of postoperative radiotherapy (PORT) in a setting of early OSCC, and highlight surgery alone as the standard single modality treatment. Notwithstanding, the negative prognostic impact of some adverse pathological features, such as perineural and lymphovascular invasion, poor differentiation, depth of invasion >4 mm, and presence of nodal metastasis, is well known. The advantages of PORT in such scenarios are still debated. The aim of this study was to review the more recent literature to provide evidence on the benefits of PORT in the context of early stage OSCC.
KW - Adverse pathological feature
KW - Early stage oral cavity cancer
KW - Postoperative radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=85071768872&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071768872&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2019.08.003
DO - 10.1016/j.critrevonc.2019.08.003
M3 - Review article
C2 - 31499275
AN - SCOPUS:85071768872
VL - 143
SP - 67
EP - 75
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
SN - 1040-8428
ER -